Navigation Links
New Study Reports Improved Patient Outcomes for Breast Cancer Patients
Date:2/18/2009

VALENCIA, Calif., Feb. 18 /PRNewswire/ -- A new clinical study published this month in The Breast Journal (Vol. 15, No. 1) reports that high-quality patient outcomes for breast-conserving surgery can be achieved in the community hospital setting. This is one of the few and the most recent studies of its kind and is particularly relevant given that nearly two-thirds of all breast cancer patients in the United States are treated at community centers.

The study tracked 185 cases from 1997-2003 at Henry Mayo Newhall Memorial Hospital, located in the Southern California suburb of Valencia. The patients underwent a lumpectomy typically with a 5mm margin, as opposed to the 1-2mm margin performed in surgeries at most institutions. The study includes five-year follow-up data that shows a local recurrence rate of 2 percent as compared to the national norm of 4-9 percent.

"This study basically suggests a resetting of the bar on how to do lumpectomies and what patients can expect if it is done this way," said Henry Mayo's Breast Center Medical Director Gregory Senofsky, M.D. "Our findings are hard to ignore."

According to Barbara Florentine, M.D., medical director of the department of pathology at Henry Mayo and lead author of the study, the first objective of the study was to evaluate the factors known to influence outcomes. "These include tumor and patient characteristics, completeness of local surgical tumor excision, and adjuvant radiation therapy and/or chemotherapy/hormonal treatment," she says. "The second objective was to evaluate the percentage of cases in which the initial breast-conserving surgery did not achieve adequate surgical oncological results (5mm margins) and the number and type of subsequent surgeries that were required to achieve this goal."

Of the 185 cases tracked in this study, 87 percent had successful breast-conserving surgery. A single surgery was deemed sufficient to achieve the desired outcome in 54 percent of the cases while 46 percent required additional surgeries because of the 5mm requirement. Survival rates for patients undergoing this treatment at Henry Mayo compared favorably with data presented by the National Council Database reporting on outcomes at teaching/research hospitals. Disease free survival for early stage cancer was 91 percent at five years.

The flap-advancement reconstruction surgery performed by Dr. Senofsky requires a team that includes a specially trained surgeon and radiologist plus the presence of a pathologist in the operating room to provide real-time information. "The procedure requires extra work and extra training in how radiologists insert the wires and how surgeons approach their craft relative to performing larger targeted lumpectomies with excellent cosmetic results, but it is what patients should come to expect based on our study," he said.

"It is difficult to successfully obtain adequate excision of the cancer while still maintaining a beautiful breast with no distortions--and that's very important to a woman," stated Dr. Florentine. "Dr. Senofsky is able to achieve both through the use of oncoplastic techniques."

While Henry Mayo has no comprehensive breast center building, the hospital does provide equivalent services thanks to a well-integrated medical campus and a multi-modality breast team that meets regularly to discuss care plans tailored to the uniqueness of each patient, including age, health status, risk factors, and the patient's own desires and needs. The hospital owns and operates the pathology, breast imaging, and inpatient and outpatient surgical operating suites while on-campus radiation, medical oncology and breast surgery services are provided by independent physician groups.

The study was conducted by a nine-person investigative team, six of whom are affiliated with Henry Mayo. Leading the study were Drs. Senofsky and Barbara Florentine. In addition to his role at Henry Mayo, Dr. Senofsky is a clinical faculty member at UCLA's surgical oncology department and the author of The Patient's Guide to Outstanding Breast Cancer Care. Dr. Florentine is medical director of the department of pathology and is affiliated with the department of pathology at the Keck School of Medicine at the University of Southern California. Additional Henry Mayo participants include physicians John Barstis, M.D.; Alexander Black, M.D.; and Robert Zimmerman, M.D., along with Brian Cooper, tumor registrar officer.

ABOUT HENRY MAYO - Henry Mayo Newhall Memorial Hospital is a 221-bed not-for-profit acute-care hospital serving the Santa Clarita Valley since 1975. Services include trauma, emergency, intensive care, maternity, surgery, nursing, wound care, behavioral health, and acute rehab as well as cancer, cardiology, imaging, lab, digestive, respiratory services, and physical and occupational therapies. For information, visit www.henrymayo.com or call 661-253-8000.


'/>"/>
SOURCE Henry Mayo Newhall Memorial Hospital
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... 2016 , ... PharmApprove announced today the hiring ... for Rare Disorders (NORD). Dorman will lead PharmApprove efforts to work with patients, ... drug regulatory review process. , “Adding Diane Dorman is just the latest in ...
(Date:2/9/2016)... , Feb. 9, 2016 BERG, a ... biological research approach, has announced the appointment of ... and Chief Operating Officer. Haddock brings to BERG ... including 12 years in senior financial functions at ... in business organizational management. Niven ...
(Date:2/8/2016)... --> ... oncology company developing next generation cancer therapeutics that ... that chairman emeritus of Tata Sons Limited, Mr ... as part of the first close of Invictus,s ... Capital and Aarin Capital. http://photos.prnewswire.com/prnh/20150923/766442 ) ...
(Date:2/8/2016)... ... February 08, 2016 , ... Bulk food product inspection systems ... various stages of the production process. Despite frequently inspecting loose product prior to ... packaging such as sacks of dry powders. , Mettler-Toledo Product Inspection's brand-new white ...
Breaking Biology Technology:
(Date:1/15/2016)... JUAN, Puerto Rico , Jan. 15, 2016 /PRNewswire/ ... companies big and small to find new ways to ... driven culture. iOS and Android ... device based on biometrics, transforming it into a hardware ... request that users swipe their fingerprint on their KodeKey ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
(Date:1/8/2016)... -- NXTD ), a company focused on ... privately held leading direct seller of vacation and entertainment ... company announced that on December 31, 2015, that WorldVentures ... to develop a proprietary new wireless smart card for ... unique smart wallet that serves to securely store all ...
Breaking Biology News(10 mins):